The Proactive Pharmacist: Building Menopause Knowledge and Closing Care Gaps in the Community

In this episode, 'The Proactive Pharmacist: Building Menopause Knowledge and Closing Care Gaps in the Community,' the panelists/expert pharmacists, menopause experts explore the following question:

1. How can community pharmacists position themselves more proactively as partners in treating hot flashes? What gaps can they help close?

The panelists examined the practical pathways available to community pharmacists who want to build their menopause expertise, with a strong consensus around the Menopause Society as a foundational starting point, offering position statements, continuing education, an annual meeting boot camp, and a certification pathway open to pharmacists, nurse practitioners, physical therapists, mental health counselors, and physicians alike, making it one of the most accessible and comprehensive routes to becoming a certified menopause practitioner regardless of professional background. The discussion also highlighted the value of self-directed learning through peer-reviewed literature, clinical trial databases, and resources such as Pharmacy Times, as well as the importance of forming relationships with menopause-informed colleagues as a powerful complement to formal continuing education. The panelists further emphasized that community pharmacists are uniquely positioned to close meaningful gaps in menopause care by proactively screening patients for symptoms during routine interactions, staying current on rapidly evolving treatment options, and serving as an empowering, trusted resource for women who may not yet have connected with a menopause-informed prescriber.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Navigating Coverage and Cost: What Pharmacists Need to Know About Access to Non-Hormonal VMS Therapies,' features the panelists advancing their conversation on vasomotor symptoms and menopause and focusing on the current insurance coverage landscape for fezolinetant and elinzanetant, the barriers patients and pharmacists are encountering in securing approval, and the access strategies and manufacturer resources available to help patients get the treatments they need.